浙江醫藥(600216.SH)澄清稱公司一直以來依法經營真實確認各項費用
格隆匯8月14日丨浙江醫藥(600216.SH)公佈，公司關注到近日部分媒體刊登了針對公司的相關信息(“媒體報道”)，相關報道中提及浙江醫藥分公司新昌製藥廠接受12份虛開增值税普票被通報，公司關注到媒體報道後進行了認真核實，現予以澄清説明。
媒體報道中提及武漢南瑞洋廣告有限公司向公司分公司開具虛假增值税普通發票6份，發票代碼為4200171320，發票號碼為30712515-30712520。澄清如下：
公司在2018年4月收到武漢南瑞洋廣告有限公司開具的6張增值税普通發票，發票代碼為4200171320，發票號碼為30712515-30712520，我司財務審核人員在審核該發票時，發現未簽訂相應合同且未向公司備案，遂將發票退回了相關業務人員，六張發票含税金額合計35.1萬元。2018年7月，公司接到當地税務部門對武漢南瑞洋廣告有限公司發票異常要求配合調查的通知，組織人員對公司2018年2月至7月的憑證進行翻閲檢查，確認賬上沒有列支武漢南瑞洋廣告有限公司的任何發票。以上情況2018年7月19日已經向當地税務局備案。公司與武漢南瑞洋廣告有限公司實際未發生任何業務，未來也無合作意向。
媒體報道中提及武漢達晶力廣告有限公司向我司分公司開具虛假增值税普通發票6份，發票代碼為4200171320，發票號碼為30491409-30491414。澄清如下：
公司未收到過武漢達晶力廣告有限公司開具的發票代碼為4200171320，發票號碼為30491409-30491414的6張發票，公司賬上沒有列支，也未收到過當地税務部門的核查通知。公司與武漢達晶力廣告有限公司未發生任何業務，未來也無合作意向。
公司一直以來依法經營，真實確認各項費用，目前經營情況正常。2018年銷售費用有較大幅度增長，是因為在“兩票制”政策下流通企業不承擔推廣職能，生產企業與專業推廣機構、服務公司合作，專業推廣機構、服務公司提供的推廣服務支付服務費用計入銷售費用所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
